Adma Biologics (ADMA) Assets Average (2011 - 2025)

Adma Biologics (ADMA) has 13 years of Assets Average data on file, last reported at $596.5 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 35.67% year-over-year to $596.5 million; the trailing twelve-month figure through Dec 2025 stood at $596.5 million (up 35.67% YoY), and the FY2025 full-year result was $556.5 million, up 36.08% from the prior year.
• Assets Average for Q4 2025 stood at $596.5 million, up from $563.5 million in the prior quarter.
• Across five years, Assets Average topped out at $596.5 million in Q4 2025 and bottomed at $221.7 million in Q1 2021.
• The 5-year median for Assets Average is $341.0 million (2023), against an average of $363.0 million.
• The widest annual swing landed in 2024, when Assets Average retreated 1.33%; it then surged 46.98% in 2025.
• A 5-year view of Assets Average shows it stood at $257.4 million in 2021, then gained by 26.05% to $324.5 million in 2022, then climbed by 4.49% to $339.1 million in 2023, then advanced by 29.66% to $439.6 million in 2024, then soared by 35.67% to $596.5 million in 2025.
• The last three Assets Average figures came in at $596.5 million (Q4 2025), $563.5 million (Q3 2025), and $534.5 million (Q2 2025), per Business Quant data.

Peer Comparison